SARS-CoV-2加强疫苗接种后骨髓瘤患者中变异抗体的差异及混合免疫的影响
Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity.
作者信息
Moreno Alberto, Manning Kelly, Azeem Maryam I, Nooka Ajay K, Ellis Madison, Manalo Renee Julia, Switchenko Jeffrey M, Wali Bushra, Kaufman Jonathan L, Hofmeister Craig C, Joseph Nisha S, Lonial Sagar, Dhodapkar Kavita M, Dhodapkar Madhav V, Suthar Mehul S
机构信息
Emory Vaccine Center, Emory University, Atlanta, Georgia.
Emory National Primate Research Center, Atlanta, Georgia.
出版信息
NPJ Vaccines. 2024 Oct 27;9(1):201. doi: 10.1038/s41541-024-00999-6.
Hematological malignancies are associated with an increased risk of complications during SARS-CoV-2 infections. Primary series or monovalent booster vaccines reduce disease severity, hospitalization, and death among multiple myeloma patients. We characterized virus-neutralizing and spike-binding antibody profiles following monovalent (WA1) or bivalent (WA1/BA.5) SARS-CoV-2 booster vaccination in MM patients. Bivalent vaccination improved the breadth of binding antibodies but not neutralization activity against contemporary variants. Hybrid immunity and immune imprinting impact vaccine-elicited immunity.
血液系统恶性肿瘤与感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）期间并发症风险增加相关。单价或二价加强疫苗可降低多发性骨髓瘤患者的疾病严重程度、住院率和死亡率。我们对多发性骨髓瘤（MM）患者接种单价（WA1）或二价（WA1/BA.5）SARS-CoV-2加强疫苗后的病毒中和及刺突结合抗体谱进行了特征分析。二价疫苗接种改善了结合抗体的广度，但对当代变体的中和活性没有改善。混合免疫和免疫印记会影响疫苗诱导的免疫。
Zotero 插件